JP2009537608A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537608A5
JP2009537608A5 JP2009511524A JP2009511524A JP2009537608A5 JP 2009537608 A5 JP2009537608 A5 JP 2009537608A5 JP 2009511524 A JP2009511524 A JP 2009511524A JP 2009511524 A JP2009511524 A JP 2009511524A JP 2009537608 A5 JP2009537608 A5 JP 2009537608A5
Authority
JP
Japan
Prior art keywords
antibody
seq
light chain
heavy chain
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009511524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537608A (ja
JP5420399B2 (ja
Filing date
Publication date
Priority claimed from GB0610438A external-priority patent/GB0610438D0/en
Priority claimed from GB0611046A external-priority patent/GB0611046D0/en
Application filed filed Critical
Priority claimed from PCT/EP2007/055029 external-priority patent/WO2007137984A2/en
Publication of JP2009537608A publication Critical patent/JP2009537608A/ja
Publication of JP2009537608A5 publication Critical patent/JP2009537608A5/ja
Application granted granted Critical
Publication of JP5420399B2 publication Critical patent/JP5420399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009511524A 2006-05-25 2007-05-23 改変型ヒト化抗インターロイキン−18抗体 Active JP5420399B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0610438.4 2006-05-25
GB0610438A GB0610438D0 (en) 2006-05-25 2006-05-25 Immunoglobulins
GB0611046A GB0611046D0 (en) 2006-06-05 2006-06-05 Immunoglobulins
GB0611046.4 2006-06-05
PCT/EP2007/055029 WO2007137984A2 (en) 2006-05-25 2007-05-23 Modified humanised anti-interleukin-18 antibodies

Publications (3)

Publication Number Publication Date
JP2009537608A JP2009537608A (ja) 2009-10-29
JP2009537608A5 true JP2009537608A5 (https=) 2013-07-25
JP5420399B2 JP5420399B2 (ja) 2014-02-19

Family

ID=38476914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511524A Active JP5420399B2 (ja) 2006-05-25 2007-05-23 改変型ヒト化抗インターロイキン−18抗体

Country Status (22)

Country Link
US (5) US8133978B2 (https=)
EP (1) EP2027157B1 (https=)
JP (1) JP5420399B2 (https=)
KR (1) KR101416078B1 (https=)
AR (1) AR061115A1 (https=)
AU (1) AU2007267213B2 (https=)
BR (1) BRPI0711908B8 (https=)
CA (1) CA2652733C (https=)
CR (1) CR10468A (https=)
EA (1) EA017303B1 (https=)
ES (1) ES2514495T3 (https=)
IL (1) IL194995A0 (https=)
MA (1) MA30486B1 (https=)
MX (1) MX2008014842A (https=)
MY (1) MY157173A (https=)
NO (1) NO341921B1 (https=)
NZ (1) NZ572565A (https=)
PE (1) PE20080262A1 (https=)
SG (1) SG172625A1 (https=)
TW (1) TWI422387B (https=)
WO (1) WO2007137984A2 (https=)
ZA (1) ZA200809662B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
TWI422387B (zh) 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2010020593A1 (en) * 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
MX2011001117A (es) 2008-08-27 2011-03-02 Hoffmann La Roche Metodo para cribado de anticuerpo de alta afinidad.
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
MX2012001991A (es) 2009-08-25 2012-02-29 Hoffmann La Roche Factor de velocidad.
US20120308564A1 (en) * 2010-02-09 2012-12-06 Andrew Ian Bayliffe Treatment of a metabolic disorder
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 TNF-α 결합 단백질
TWI504609B (zh) * 2010-11-23 2015-10-21 Glaxo Group Ltd 抗原結合蛋白質
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US20130149308A1 (en) * 2011-08-12 2013-06-13 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
WO2014080866A1 (ja) 2012-11-21 2014-05-30 一般財団法人化学及血清療法研究所 新規なヒト抗il-18抗体
EP2997036B1 (en) * 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
WO2017076805A1 (en) * 2015-11-02 2017-05-11 Glaxosmithkline Intellectual Property Development Limited Use of an inhibitor of il18 for treatment of acute kidney injury
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Il-6阻害剤を含有する喘息の治療剤
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP4159236A4 (en) 2020-05-29 2024-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
KR20230110291A (ko) 2020-11-18 2023-07-21 노파르티스 아게 Nlrc4-gof 염증복합체병증의 치료에 사용하기 위한 이중특이적 항체
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
WO2023056193A2 (en) * 2021-09-29 2023-04-06 Chimera Bioengineering, Inc. Il-18 variants and uses thereof
CN121586728A (zh) 2023-06-20 2026-02-27 阿波罗Ap43有限公司 用于治疗特应性皮炎的抗il-18抗体疗法
WO2025229563A1 (en) * 2024-05-03 2025-11-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating inflammatory bowel disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
DK0528767T3 (da) 1991-08-21 2000-04-17 Novartis Ag antistofderivater
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
JP2952750B2 (ja) * 1995-02-23 1999-09-27 株式会社林原生物化学研究所 モノクローナル抗体
PT971959E (pt) * 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
ME00546B (me) 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
WO2002066063A1 (en) 2001-02-23 2002-08-29 Nippon Organon K.K. Remedies for metabolic bone diseases
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
UA78516C2 (en) 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
CA2523912A1 (en) 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
PT1730191E (pt) 2004-03-30 2011-10-04 Glaxo Group Ltd Imunoglobulina que se liga a hosm
GB0425556D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
EP1987066B1 (en) 2006-02-22 2010-12-29 University of Zürich Methods for treating demyelinating diseases
TWI422387B (zh) * 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
WO2010020593A1 (en) 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists

Similar Documents

Publication Publication Date Title
JP2009537608A5 (https=)
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
CN108367075B (zh) 4-1bb结合蛋白及其用途
JP2022061992A5 (https=)
Almagro et al. Humanization of antibodies
JP2015504306A5 (https=)
CN104774266B (zh) 白介素-13结合蛋白
JP2014534242A5 (https=)
RU2009124591A (ru) Соединения
JP2018526981A5 (https=)
JP2010524435A5 (https=)
RU2004135103A (ru) Антитела, специфичные к cd22 человека, и их применения в терапии и диагностике
JP2012505654A (ja) 抗体をヒト化及び親和性成熟する方法
RU2009128064A (ru) Антитела к cd44
AU2013291937A1 (en) Antibodies to highly conserved targets
JP2022516881A5 (https=)
RU2008137763A (ru) Связующий элемент для рецептора gm-csf
TW201014602A (en) Prostaglandin E2 binding proteins and uses thereof
JP2010535012A5 (https=)
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
JP2022521705A5 (https=)
JP2013509158A5 (https=)
TW201127401A (en) Compositions and methods for treating inflammatory disorders
US20110223176A1 (en) Basigin binding proteins